Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy

Fig. 3

Shrinkage patterns of non-mass lesions. a concentric shrinkage (CS): simple CS (pretreatment: a regional 62 mm non-mass, early neoadjuvant therapy [NAT]: tumor size decreased to 27 mm without any morphological changes), b CS: CS plus decreased enhancement (pretreatment: a multiple regions 54 mm non-mass, early NAT: tumor size decreased to 44 mm with significantly reduced enhancement) c diffuse decrease (DD): CS with surrounding lesions (pretreatment: a segmental 100 mm non-mass, early NAT: the main lesion showed CS with peripheral focal lesions), d DD: shrinkage with residual multinodular lesions (pretreatment: a diffuse 75 mm non-mass, early NAT: tumor splits into uniform small fragments mixed with fibrous stroma), e decrease of intensity only (DIO) (pretreatment: a regional 60 mm non-mass, early NAT: the degree of enhancement was obviously reduced but unchanged size), f stable disease (SD) (pretreatment: a diffuse non-mass, early NAT: no changes). No CS to small foci non-mass lesions in our study

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us